{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Blood is measured for a detectable level of LMB-100 in the blood. LMB-100 is either detectable in the blood or not. A detectable level of LMB-100 in the blood is considered a desirable outcome for the participant. Hence, the reverse is not a considered a desirable outcome for the participant.","groups":[{"description":"Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses\n\nLMB-100: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles\n\nSEL-110: administered on day 1 of each cycle for up to 4 cycles","id":"OG000","title":"140 mcg/kg"},{"description":"Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses\n\nLMB-100: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles\n\nSEL-110: administered on day 1 of each cycle for up to 4 cycles","id":"OG001","title":"100 mcg/kg"}],"populationDescription":"This outcome measure was not done because the study was closed due to a fatal occurrence of pneumonitis that was attributed to one of the study drugs.","reportingStatus":"POSTED","timeFrame":"Day 85","title":"Fraction of Participants With Detectable LMB-100 in Blood After Cycle 4","type":"SECONDARY"}